Alternating vector immunizations encoding pre-erythrocytic malaria antigens enhance memory responses in a malaria endemic area

被引:18
作者
Bejon, Philip
Kai, Oscar K.
Mwacharo, Jedidah
Keating, Sheila
Lang, Trudie
Gilbert, Sarah C.
Peshu, Norbert
Marsh, Kevin
Hill, Adrian V. S.
机构
[1] Ctr Geog Med Res Coast, Kenya Med Res Inst, Kilifi, Kenya
[2] Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford, England
[3] Univ Oxford, Ctr Clin Vaccinol & Trop Med, Oxford, England
[4] Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Med, Oxford OX3 9DU, England
基金
英国惠康基金;
关键词
human; memory; T cells; vaccination;
D O I
10.1002/eji.200636187
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 [免疫学];
摘要
A heterologous prime-boost strategy has been developed to potently induce T cell responses to pre-erythrocytic malaria antigens. Efficacy in the field is likely to depend on both peak immunogenicity and the durability of responses. To improve both immunogenicity and durability of responses, 54 adult males from a malaria endemic area were immunized with different vaccination regimens, systematically varying antigenic insert and the number and sequence of component vaccinations. The component vaccinations were recombinant attenuated viruses, either fowlpox (FP) 9 or modified vaccinia virus Ankara (MVA). These were recombinant for either of two pre-erythrocytic malaria antigens (multiple epitope-thrombospondin-related adhesion protein, ME-TRAP, or circumsporozoite antigen (CS). ELISPOT assays were used to measure the effector and resting memory T cell responses. Sequence, antigen insert and number of vaccinations influenced immunogenicity, but the novel alternating vector immunizations generated the largest resting memory T cell populations. Effector responses were maintained at 84% of the peak response after 270 days. This durability of response is unprecedented. Classical prime-boost vaccination responses were at 5% of the peak after 270 days. Vaccines administered by heterologous prime-boost regimes are being developed for diverse pathogens and cancer. These data suggest these vaccines should also be administered by alternating vector regimens in clinical development.
引用
收藏
页码:2264 / 2272
页数:9
相关论文
共 23 条
[1]
Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children:: randomised controlled trial [J].
Alonso, PL ;
Sacarlal, J ;
Aponte, JJ ;
Leach, A ;
Macete, E ;
Milman, J ;
Mandomando, I ;
Spiessens, B ;
Guinovart, C ;
Espasa, M ;
Bassat, Q ;
Aide, P ;
Ofori-Anyinam, O ;
Navia, MM ;
Corachan, S ;
Ceuppens, M ;
Dubois, MC ;
Demoitié, MA ;
Dubovsky, F ;
Menéndez, C ;
Tornieporth, N ;
Ballou, WR ;
Thompson, R ;
Cohen, J .
LANCET, 2004, 364 (9443) :1411-1420
[2]
CD8+ T cell contraction is controlled by early inflammation [J].
Badovinac, VP ;
Porter, BB ;
Harty, JT .
NATURE IMMUNOLOGY, 2004, 5 (08) :809-817
[3]
Accelerated CD8+ T-cell memory and prime-boost response after dendritic-cell vaccination [J].
Badovinac, VP ;
Messingham, KAN ;
Jabbari, A ;
Haring, JS ;
Harty, JT .
NATURE MEDICINE, 2005, 11 (07) :748-756
[4]
Safety profile of the viral vectors of attenuated fowlpox strain FP9 and modified vaccinia virus Ankara recombinant for either of 2 preerythrocytic malaria antigens, ME-TRAP or the circumsporozoite protein, in children and adults in Kenya [J].
Bejon, P ;
Peshu, N ;
Gilbert, SC ;
Lowe, BS ;
Molyneux, CS ;
Forsdyke, J ;
Lang, T ;
Hill, AVS ;
Marsh, K .
CLINICAL INFECTIOUS DISEASES, 2006, 42 (08) :1102-1110
[5]
Enhanced protective immunity against malaria by vaccination with a recombinant adenovirus encoding the circumsporozoite protein of Plasmodium lacking the GPI-anchoring motif [J].
Bruna-Romero, O ;
Rocha, CD ;
Tsuji, M ;
Gazzinelli, RT .
VACCINE, 2004, 22 (27-28) :3575-3584
[6]
T cells undergo rapid ON/OFF but not ON/OFF/ON cycling of cytokine production in response to antigen [J].
Corbin, GA ;
Harty, JT .
JOURNAL OF IMMUNOLOGY, 2005, 174 (02) :718-726
[7]
The complexity of protective immunity against liver-stage malaria [J].
Doolan, DL ;
Hoffman, SL .
JOURNAL OF IMMUNOLOGY, 2000, 165 (03) :1453-1462
[8]
A clinical trial of prime-boost immunisation with the candidate malaria vaccines RTS,S/AS02A and MVA-CS [J].
Dunachie, SJ ;
Walther, M ;
Vuola, JM ;
Webster, DP ;
Keating, SM ;
Berthoud, T ;
Andrews, L ;
Bejon, P ;
Poulton, I ;
Butcher, G ;
Watkins, K ;
Sinden, RE ;
Leach, A ;
Moris, P ;
Tornieporth, N ;
Schneider, J ;
Dubovsky, F ;
Tierney, E ;
Williams, J ;
Heppner, DG ;
Gilbert, SC ;
Cohen, J ;
Hill, AVS .
VACCINE, 2006, 24 (15) :2850-2859
[9]
Unique T cell effector functions elicited by Plasmodium falciparum epitopes in malaria-exposed Africans tested by three T cell assays [J].
Flanagan, KL ;
Lee, EAM ;
Gravenor, MB ;
Reece, WHH ;
Urban, BC ;
Doherty, T ;
Bojang, KA ;
Pinder, M ;
Hill, AVS ;
Plebanski, M .
JOURNAL OF IMMUNOLOGY, 2001, 167 (08) :4729-4737
[10]
A protein particle vaccine containing multiple malaria epitopes [J].
Gilbert, SC ;
Plebanski, M ;
Harris, SJ ;
Allsopp, CEM ;
Thomas, R ;
Layton, GT ;
Hill, AVS .
NATURE BIOTECHNOLOGY, 1997, 15 (12) :1280-1284